Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
5.29
-0.01 (-0.19%)
Aug 15, 2025, 9:59 AM - Market open

Aldeyra Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-50.62-55.85-37.54-62.02-57.78-37.55
Upgrade
Depreciation & Amortization
0.250.250.260.260.260.06
Upgrade
Other Amortization
0.27-----
Upgrade
Asset Writedown & Restructuring Costs
-----1.75
Upgrade
Loss (Gain) From Sale of Investments
-1.81-1.67-0.01-0.05--0.09
Upgrade
Stock-Based Compensation
6.917.975.758.297.117.08
Upgrade
Other Operating Activities
0.20.180.350.330.410.09
Upgrade
Change in Accounts Payable
0.78-1.161.2-0.890.64-0.43
Upgrade
Change in Unearned Revenue
--6---
Upgrade
Change in Other Net Operating Assets
2.997.07-6.34-2.566.8-8.4
Upgrade
Operating Cash Flow
-41.04-43.21-30.33-56.64-42.56-37.49
Upgrade
Capital Expenditures
----0.02-0.01-
Upgrade
Investment in Securities
10.44-44.9230-29.94-29.02
Upgrade
Investing Cash Flow
10.44-44.9230-29.95-0.0129.02
Upgrade
Long-Term Debt Repaid
--0.29-1.04---
Upgrade
Total Debt Repaid
-0.29-0.29-1.04---
Upgrade
Net Debt Issued (Repaid)
-0.29-0.29-1.04---
Upgrade
Issuance of Common Stock
1.370.390.311.22194.541.9
Upgrade
Repurchase of Common Stock
---0.53---
Upgrade
Other Financing Activities
-0.27-0.27----
Upgrade
Financing Cash Flow
0.81-0.17-1.271.22194.541.9
Upgrade
Net Cash Flow
-29.79-88.3-1.6-85.37151.9333.43
Upgrade
Free Cash Flow
-41.04-43.21-30.33-56.65-42.56-37.49
Upgrade
Free Cash Flow Per Share
-0.69-0.73-0.51-0.97-0.79-1.10
Upgrade
Cash Interest Paid
1.711.751.71.341.341.39
Upgrade
Levered Free Cash Flow
17.62-17.06-27.6292.19-123.6-20.28
Upgrade
Unlevered Free Cash Flow
18.81-15.86-26.3293.25-122.51-19.09
Upgrade
Change in Working Capital
3.775.910.86-3.447.44-8.83
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q